Transactions
30
Insider / Merck & Co., Inc.
Karsanbhai Surendralal Lanca
Director at Merck & Co., Inc.
- Company
- Merck & Co., Inc.
- First filing on record
- November 5, 2025
- Latest trade on record
- September 30, 2026
- SEC filings
- EDGAR ↗
Karsanbhai Surendralal Lanca, Director at Merck & Co., Inc., has disclosed 30 transactions in MRK, EMR since November 5, 2025: 0 purchases (0 open-market buys) and 9 sales, worth about $18.2M at the reported prices. The latest was filed October 1, 2026, 1 day after the trade.
Open-market buys
0
Sales
9
Avg. disclosure lag
1.5d
Trading in charts
Trade timeline
When does this person trade, how big, and in which direction? Every trade in the last 12 months.
Bought (above the line)Sold (below the line)Other transaction
In the last 12 months Karsanbhai Surendralal Lanca made no purchases and 9 sales worth $17M, plus 21 other transactions. Dot size is the dollar amount.
Portfolio mix
Which stocks does this person trade most? Tile size is dollars traded, all time on record.
Karsanbhai Surendralal Lanca has traded 1 stock on record; the largest by dollars is EMR.
Reporting lag
Does this person report on time? One bar per filing against the Form 4 deadline.
On timeLate
0 of 14 filings on record were reported after the Form 4 deadline (two business days, counted here as 4 calendar days).
What kind of transactions
Most Form 4 rows are pay arriving or tax being withheld, not a decision to buy or sell. Only code P is an open-market purchase and code S an open-market sale. What each code means: Form 4 transaction codes.
| Code | Meaning | Rows | Shares | Value |
|---|---|---|---|---|
| A | Grant or award | 11 | 685,859 | $252K |
| F | Shares withheld for tax | 6 | 100,138 | $13.9M |
| G | Gift | 6 | 135,368 | — |
| M | Option exercise or conversion | 4 | 30,000 | $683K |
| S | Open-market sale | 3 | 22,613 | $3.3M |
| Year | Rows | Bought | Sold |
|---|---|---|---|
| 2026 | 8 | 0 | 3 · $3.0M |
| 2025 | 22 | 0 | 6 · $14.2M |
Transactions
| Security | Side | Trade date | Disclosed | Lag | Shares | Price | Value | Flags | Source | Share |
|---|---|---|---|---|---|---|---|---|---|---|
| MRK | Other A | September 30, 2026 | October 1, 2026 | 1d | 112 | $145 | $16K | derivative | Form 4 ↗ | |
| EMR | Sell S | August 11, 2026 | August 12, 2026 | 1d | 9,650 | $162 | $1.6M | indirect | Form 4 ↗ | |
| MRK | Other A | June 30, 2026 | July 1, 2026 | 1d | 126 | $129 | $16K | derivative | Form 4 ↗ | |
| MRK | Other A | May 29, 2026 | June 2, 2026 | 4d | 1,853 | $119 | $220K | derivative | Form 4 ↗ | |
| EMR | Sell S | March 10, 2026 | March 12, 2026 | 2d | 5,700 | $142 | $811K | indirect | Form 4 ↗ | |
| EMR | Other G | February 5, 2026 | February 6, 2026 | 1d | 5,578 | — | — | indirect | Form 4 ↗ | |
| EMR | Other G | February 5, 2026 | February 6, 2026 | 1d | 5,578 | — | — | Form 4 ↗ | ||
| EMR | Sell F | February 2, 2026 | February 4, 2026 | 2d | 4,422 | $148 | $655K | Form 4 ↗ | ||
| EMR | Other G | December 15, 2025 | December 16, 2025 | 1d | 3,120 | — | — | indirect | Form 4 ↗ | |
| EMR | Other G | December 15, 2025 | December 16, 2025 | 1d | 3,120 | — | — | Form 4 ↗ | ||
| EMR | Option / conversion M | December 3, 2025 | December 4, 2025 | 1d | 10,227 | — | — | derivative | Form 4 ↗ | |
| EMR | Option / conversion M | December 2, 2025 | December 4, 2025 | 2d | 4,773 | — | — | derivative | Form 4 ↗ | |
| EMR | Other G | December 4, 2025 | December 4, 2025 | 0d | 2,267 | — | — | indirect | Form 4 ↗ | |
| EMR | Sell S | December 3, 2025 | December 4, 2025 | 1d | 7,263 | $133 | $966K | Form 4 ↗ | ||
| EMR | Sell F | December 3, 2025 | December 4, 2025 | 1d | 2,964 | $133 | $394K | Form 4 ↗ | ||
| EMR | Option / conversion M | December 3, 2025 | December 4, 2025 | 1d | 10,227 | $46 | $465K | Form 4 ↗ | ||
| EMR | Sell F | December 2, 2025 | December 4, 2025 | 2d | 1,653 | $131 | $217K | Form 4 ↗ | ||
| EMR | Option / conversion M | December 2, 2025 | December 4, 2025 | 2d | 4,773 | $46 | $217K | Form 4 ↗ | ||
| EMR | Other A | November 25, 2025 | November 26, 2025 | 1d | 115,705 | — | — | indirect | Form 4 ↗ | |
| EMR | Other G | November 25, 2025 | November 26, 2025 | 1d | 115,705 | — | — | Form 4 ↗ | ||
| EMR | Other A | November 13, 2025 | November 14, 2025 | 1d | 70,000 | — | — | derivative | Form 4 ↗ | |
| EMR | Other A | November 13, 2025 | November 14, 2025 | 1d | 70,000 | — | — | derivative | Form 4 ↗ | |
| EMR | Other A | November 13, 2025 | November 14, 2025 | 1d | 70,000 | — | — | derivative | Form 4 ↗ | |
| EMR | Other A | November 13, 2025 | November 14, 2025 | 1d | 70,000 | — | — | derivative | Form 4 ↗ | |
| EMR | Other A | November 13, 2025 | November 14, 2025 | 1d | 70,000 | — | — | derivative | Form 4 ↗ | |
| EMR | Sell F | November 6, 2025 | November 10, 2025 | 4d | 10,016 | $133 | $1.3M | Form 4 ↗ | ||
| EMR | Sell F | November 4, 2025 | November 6, 2025 | 2d | 9,022 | $138 | $1.2M | Form 4 ↗ | ||
| EMR | Other A | November 3, 2025 | November 5, 2025 | 2d | 54,475 | — | — | Form 4 ↗ | ||
| EMR | Sell F | November 3, 2025 | November 5, 2025 | 2d | 72,061 | $139 | $10.0M | Form 4 ↗ | ||
| EMR | Other A | November 3, 2025 | November 5, 2025 | 2d | 163,588 | — | — | Form 4 ↗ |
Filings
| Filed | Form | Accession | Rows | Status | Source |
|---|---|---|---|---|---|
| October 1, 2026 | Form 4 | 0000310158-26-000232 | 1 | published | EDGAR ↗ |
| August 12, 2026 | Form 4 | 0000950138-26-000021 | 1 | published | EDGAR ↗ |
| July 1, 2026 | Form 4 | 0000310158-26-000200 | 1 | published | EDGAR ↗ |
| June 2, 2026 | Form 4 | 0000310158-26-000171 | 1 | published | EDGAR ↗ |
| March 12, 2026 | Form 4 | 0001754881-26-000006 | 1 | published | EDGAR ↗ |
| February 6, 2026 | Form 4 | 0001754881-26-000004 | 2 | published | EDGAR ↗ |
| February 4, 2026 | Form 4 | 0001754881-26-000002 | 1 | published | EDGAR ↗ |
| December 16, 2025 | Form 4 | 0001754881-25-000019 | 2 | published | EDGAR ↗ |
| December 4, 2025 | Form 4 | 0001754881-25-000017 | 8 | published | EDGAR ↗ |
| November 26, 2025 | Form 4 | 0001754881-25-000014 | 2 | published | EDGAR ↗ |
| November 14, 2025 | Form 4 | 0001754881-25-000011 | 5 | published | EDGAR ↗ |
| November 10, 2025 | Form 4 | 0001754881-25-000007 | 1 | published | EDGAR ↗ |
| November 6, 2025 | Form 4 | 0001754881-25-000005 | 1 | published | EDGAR ↗ |
| November 5, 2025 | Form 4 | 0001754881-25-000003 | 3 | published | EDGAR ↗ |
Other insiders at Merck & Co., Inc.
- Newstead Jennifer SVP, GC and Government Affairs 47 rows
- Lee Lori M Director 38 rows
- Krishnan Ram R. Executive Vice Pres & COO 20 rows
- Zachary Jennifer EVP, General Counsel 20 rows
- BLINN MARK A Director 19 rows
- Warden Kathy J Chair, CEO and President 19 rows
- Williams David Michael EVP,Chief Info&Digital Officer 19 rows
- RUSSO PATRICIA F Director 16 rows
- Smart Dalton E. III SVP Fin. - Global Controller 16 rows
- DeLuca Richard R. EVP&Pres, Merck Animal Heallth 15 rows
Everyone on file, with contracts and lobbying under the company's name: Merck & Co., Inc..
Guides for this page
- What is SEC Form 4? Who files: officers, directors and owners of more than 10% of a class of the company's shares.
- Form 4 transaction codes P = purchase. S = sale. These are the two market trades.
- Insider buying vs insider selling Selling outweighs buying by a wide margin in normal times.
- Options and derivatives on Form 4 Table I = shares. Table II = options and other derivatives.
- What disclosure data cannot tell you Filings are late by design: up to 45 days for Congress, two business days for insiders.
Sources and method
| Source | Filings | Rows | First filed | Newest filed | Read the originals |
|---|---|---|---|---|---|
| SEC EDGAR, Form 4 | 14 | 30 | November 5, 2025 | October 1, 2026 | Form 4 list on EDGAR |
Site built October 27, 2026. Every row in the tables above links to its own filing. To quote a figure, use the Cite button at the top of the page; see how to cite and reuse.
Every row comes from the reporting owner's Form 4 as filed with the SEC (EDGAR ownership XML), read daily. "Value" is shares × the reported price; code P is an open-market purchase, S a sale, M an option exercise, A a grant. The lag is the filing date minus the trade date; Form 4 is due within two business days. Amendments (4/A) are not merged. Details on the methodology page; report an error on corrections.
Not investment advice. Figures are public disclosures shown as filed; they may lag the trade and may be amended later. No recommendation is made or implied.